JP2007537268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007537268A5 JP2007537268A5 JP2007513304A JP2007513304A JP2007537268A5 JP 2007537268 A5 JP2007537268 A5 JP 2007537268A5 JP 2007513304 A JP2007513304 A JP 2007513304A JP 2007513304 A JP2007513304 A JP 2007513304A JP 2007537268 A5 JP2007537268 A5 JP 2007537268A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- aliphatic
- group
- chloro
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *N(CC1)CCC1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cc2)ccc2F)=NC2)c2cn1)=O Chemical compound *N(CC1)CCC1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cc2)ccc2F)=NC2)c2cn1)=O 0.000 description 34
- MWLFQGAIUUZLMF-UHFFFAOYSA-N CC(C)(C(Nc(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O)N Chemical compound CC(C)(C(Nc(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O)N MWLFQGAIUUZLMF-UHFFFAOYSA-N 0.000 description 2
- JIAGXOBZNQXQLP-UHFFFAOYSA-N CC(C1)NC(C)CN1C(c(cc1)cc(C(c(cccc2)c2F)=NC2)c1-c1c2cnc(Nc2cccc(OC)c2)n1)=O Chemical compound CC(C1)NC(C)CN1C(c(cc1)cc(C(c(cccc2)c2F)=NC2)c1-c1c2cnc(Nc2cccc(OC)c2)n1)=O JIAGXOBZNQXQLP-UHFFFAOYSA-N 0.000 description 2
- BPWHGIJLRXHJHH-UHFFFAOYSA-N CCOC(C1NC(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3C(c(c(F)ccc3)c3F)=NC3)c3cn2)=NC1)=O Chemical compound CCOC(C1NC(c(cc2)ccc2Nc2nc(-c(ccc(Cl)c3)c3C(c(c(F)ccc3)c3F)=NC3)c3cn2)=NC1)=O BPWHGIJLRXHJHH-UHFFFAOYSA-N 0.000 description 2
- XIQGCAMBPMXNID-PLNGDYQASA-N C/C(/C=O)=C(\C)/N Chemical compound C/C(/C=O)=C(\C)/N XIQGCAMBPMXNID-PLNGDYQASA-N 0.000 description 1
- OODUQWBIRNVCGB-UHFFFAOYSA-N C=C(c(cc1)ncc1C(O)=O)c1nc(-c(c(C(c(cccc2)c2F)=NC2)c3)ccc3Cl)c2cn1 Chemical compound C=C(c(cc1)ncc1C(O)=O)c1nc(-c(c(C(c(cccc2)c2F)=NC2)c3)ccc3Cl)c2cn1 OODUQWBIRNVCGB-UHFFFAOYSA-N 0.000 description 1
- HNOJJSCJLCGGCR-UHFFFAOYSA-N CC(C(O)=O)NC(c1ccc(C(C)c2nc(-c(ccc(Cl)c3)c3C(c(cccc3)c3F)=NC3)c3cn2)cc1)=O Chemical compound CC(C(O)=O)NC(c1ccc(C(C)c2nc(-c(ccc(Cl)c3)c3C(c(cccc3)c3F)=NC3)c3cn2)cc1)=O HNOJJSCJLCGGCR-UHFFFAOYSA-N 0.000 description 1
- UEOKIKQGOFBIMC-UHFFFAOYSA-N CC(C1)NC(C)CN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)c2)ccc2F)=NC2)c2cn1)=O Chemical compound CC(C1)NC(C)CN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)c2)ccc2F)=NC2)c2cn1)=O UEOKIKQGOFBIMC-UHFFFAOYSA-N 0.000 description 1
- ZCAIBCLXMDOENG-UHFFFAOYSA-N CC(C1)NC(C)CN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2Cl)=NC2)c2cn1)=O Chemical compound CC(C1)NC(C)CN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2Cl)=NC2)c2cn1)=O ZCAIBCLXMDOENG-UHFFFAOYSA-N 0.000 description 1
- SGPLKDXBSQWSBP-UHFFFAOYSA-N CC(C1)NC(C)CN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(OC)c2)ccc2OC)=NC2)c2cn1)=O Chemical compound CC(C1)NC(C)CN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(OC)c2)ccc2OC)=NC2)c2cn1)=O SGPLKDXBSQWSBP-UHFFFAOYSA-N 0.000 description 1
- PGCYCKUBIDACLU-UHFFFAOYSA-N CC(C1)NCCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2Cl)=NC2)c2cn1)=O Chemical compound CC(C1)NCCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2Cl)=NC2)c2cn1)=O PGCYCKUBIDACLU-UHFFFAOYSA-N 0.000 description 1
- VJPPCVNINZHUKN-UHFFFAOYSA-N CC(c(cc1)ccc1N)c1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1 Chemical compound CC(c(cc1)ccc1N)c1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1 VJPPCVNINZHUKN-UHFFFAOYSA-N 0.000 description 1
- PUEVFZUTYWDOSX-RUZDIDTESA-N CCOC([C@@H](CCN)NC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O)=O Chemical compound CCOC([C@@H](CCN)NC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O)=O PUEVFZUTYWDOSX-RUZDIDTESA-N 0.000 description 1
- KGUZSLJXRRMDEW-UHFFFAOYSA-N CCc(cc1)cc(C(c2ccccc2F)=NC2)c1-c1c2cnc(Cc(cc2)ccc2C(C2CCN(C)CC2)=O)n1 Chemical compound CCc(cc1)cc(C(c2ccccc2F)=NC2)c1-c1c2cnc(Cc(cc2)ccc2C(C2CCN(C)CC2)=O)n1 KGUZSLJXRRMDEW-UHFFFAOYSA-N 0.000 description 1
- DJEDXBLNBAIGES-UHFFFAOYSA-N CN(C)C(CC1)CCN1C(c(ccc(Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)c1)c1Cl)=O Chemical compound CN(C)C(CC1)CCN1C(c(ccc(Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)c1)c1Cl)=O DJEDXBLNBAIGES-UHFFFAOYSA-N 0.000 description 1
- GOKSUBYHVSNOEO-UHFFFAOYSA-N CN(C)CC(Nc(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O Chemical compound CN(C)CC(Nc(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O GOKSUBYHVSNOEO-UHFFFAOYSA-N 0.000 description 1
- RFUOOBNVPMIZBD-UHFFFAOYSA-N CN(C)CCCN(C)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2F)=NC2)c2cn1)=O Chemical compound CN(C)CCCN(C)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2F)=NC2)c2cn1)=O RFUOOBNVPMIZBD-UHFFFAOYSA-N 0.000 description 1
- AUGLHTGPRBHFEB-UHFFFAOYSA-N CN(C1CN(C)CC1)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2F)=NC2)c2cn1)=O Chemical compound CN(C1CN(C)CC1)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2F)=NC2)c2cn1)=O AUGLHTGPRBHFEB-UHFFFAOYSA-N 0.000 description 1
- BSHOQLHPKVTOOU-UHFFFAOYSA-N CN(CC1)CCN1C(Cc(cc1)ccc1Nc1nc(-c(c(C(c(cccc2)c2F)=NC2)c3)ccc3Cl)c2cn1)=O Chemical compound CN(CC1)CCN1C(Cc(cc1)ccc1Nc1nc(-c(c(C(c(cccc2)c2F)=NC2)c3)ccc3Cl)c2cn1)=O BSHOQLHPKVTOOU-UHFFFAOYSA-N 0.000 description 1
- BAOOTCDCPBKPGA-UHFFFAOYSA-N CN(CC1)CCN1C(Cc1cccc(Nc2nc(-c(ccc(Cl)c3)c3C(c(cccc3)c3F)=NC3)c3cn2)c1)=O Chemical compound CN(CC1)CCN1C(Cc1cccc(Nc2nc(-c(ccc(Cl)c3)c3C(c(cccc3)c3F)=NC3)c3cn2)c1)=O BAOOTCDCPBKPGA-UHFFFAOYSA-N 0.000 description 1
- DVHYWGUDQNNVIN-UHFFFAOYSA-N CN(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2Cl)=NC2)c2cn1)=O Chemical compound CN(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2Cl)=NC2)c2cn1)=O DVHYWGUDQNNVIN-UHFFFAOYSA-N 0.000 description 1
- BFPAPLYZOBLOCM-UHFFFAOYSA-N CN(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2OC)=NC2)c2cn1)=O Chemical compound CN(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2OC)=NC2)c2cn1)=O BFPAPLYZOBLOCM-UHFFFAOYSA-N 0.000 description 1
- KUOQAGWUGXBGEF-UHFFFAOYSA-N CN(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c2ccccc2F)=NC2)c2cn1)=O Chemical compound CN(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c2ccccc2F)=NC2)c2cn1)=O KUOQAGWUGXBGEF-UHFFFAOYSA-N 0.000 description 1
- BVMHOVCBSVCQEC-UHFFFAOYSA-N CN(CCCN)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2F)=NC2)c2cn1)=O Chemical compound CN(CCCN)C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2F)=NC2)c2cn1)=O BVMHOVCBSVCQEC-UHFFFAOYSA-N 0.000 description 1
- JXDVLJCKEXTWFW-UHFFFAOYSA-N CNC(C(C1)NCCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O)=O Chemical compound CNC(C(C1)NCCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O)=O JXDVLJCKEXTWFW-UHFFFAOYSA-N 0.000 description 1
- ICSJKQPLYDZNMO-UHFFFAOYSA-N CNC(C1)CN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2F)=CC2)c2cn1)=O Chemical compound CNC(C1)CN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2F)=CC2)c2cn1)=O ICSJKQPLYDZNMO-UHFFFAOYSA-N 0.000 description 1
- OSJRQHRPZMEELV-UHFFFAOYSA-N CNC(CC1)CCN1C(CC(c(cc1)ccc1NC[n+]1cc(CN=C(c2c-3ccc(Cl)c2)c(c(F)ccc2)c2F)c-3[n-]1)=O)=N Chemical compound CNC(CC1)CCN1C(CC(c(cc1)ccc1NC[n+]1cc(CN=C(c2c-3ccc(Cl)c2)c(c(F)ccc2)c2F)c-3[n-]1)=O)=N OSJRQHRPZMEELV-UHFFFAOYSA-N 0.000 description 1
- WIZVBPSFRAEIQX-UHFFFAOYSA-N CNC(CC1)CCN1C(c(c(Cl)c1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O Chemical compound CNC(CC1)CCN1C(c(c(Cl)c1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O WIZVBPSFRAEIQX-UHFFFAOYSA-N 0.000 description 1
- GMGDXUNAZFDGOM-UHFFFAOYSA-N CNC(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O Chemical compound CNC(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O GMGDXUNAZFDGOM-UHFFFAOYSA-N 0.000 description 1
- MVIPPCFFGJFJAE-UHFFFAOYSA-N CNCCNc(cccc1F)c1C(c1c-2ccc(Cl)c1)=NCc1c-2nc(Nc(cc2)ccc2C(O)=O)nc1 Chemical compound CNCCNc(cccc1F)c1C(c1c-2ccc(Cl)c1)=NCc1c-2nc(Nc(cc2)ccc2C(O)=O)nc1 MVIPPCFFGJFJAE-UHFFFAOYSA-N 0.000 description 1
- OKDFRKWJNUNWCK-UHFFFAOYSA-N COC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2F)c2F)=NC2)c2cn1)=O Chemical compound COC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2F)c2F)=NC2)c2cn1)=O OKDFRKWJNUNWCK-UHFFFAOYSA-N 0.000 description 1
- PXQOEZNTCSSTCQ-UHFFFAOYSA-N COc(c(C(O)=O)c1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2F)=NC2)c2cn1 Chemical compound COc(c(C(O)=O)c1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2F)=NC2)c2cn1 PXQOEZNTCSSTCQ-UHFFFAOYSA-N 0.000 description 1
- QWZVSCMYUUBQRR-UHFFFAOYSA-N COc(cc1)cc(C(c(cccc2)c2F)=NC2)c1-c1c2cnc(Nc(cc2)ccc2C(O)=O)n1 Chemical compound COc(cc1)cc(C(c(cccc2)c2F)=NC2)c1-c1c2cnc(Nc(cc2)ccc2C(O)=O)n1 QWZVSCMYUUBQRR-UHFFFAOYSA-N 0.000 description 1
- SDKQZSMQYJJUQC-UHFFFAOYSA-N COc1cc(NC[n+]2cc(CN=C(c(cccc3)c3F)c3c-4ccc(C(NCCN5CCOCC5)=O)c3)c-4[n-]2)ccc1 Chemical compound COc1cc(NC[n+]2cc(CN=C(c(cccc3)c3F)c3c-4ccc(C(NCCN5CCOCC5)=O)c3)c-4[n-]2)ccc1 SDKQZSMQYJJUQC-UHFFFAOYSA-N 0.000 description 1
- ZIHUEWMLLVXOOF-UHFFFAOYSA-N COc1cc(Nc2ncc(CN=C(c(cccc3)c3F)c3c-4ccc(C(NCCN5CCOCC5)=O)c3)c-4n2)ccc1 Chemical compound COc1cc(Nc2ncc(CN=C(c(cccc3)c3F)c3c-4ccc(C(NCCN5CCOCC5)=O)c3)c-4n2)ccc1 ZIHUEWMLLVXOOF-UHFFFAOYSA-N 0.000 description 1
- KVSNQCVGWYJIQA-UHFFFAOYSA-N COc1ccc(Cc2nc(-c(cc(c(Cl)c3)Cl)c3C(c(cccc3)c3F)=NC3)c3cn2)cc1OC Chemical compound COc1ccc(Cc2nc(-c(cc(c(Cl)c3)Cl)c3C(c(cccc3)c3F)=NC3)c3cn2)cc1OC KVSNQCVGWYJIQA-UHFFFAOYSA-N 0.000 description 1
- ARRVXNUBNFJVGT-UHFFFAOYSA-N Cc1c(Nc(cc2)ccc2C(NCCc2ccncc2)=O)ncc2c1-c(ccc(Cl)c1)c1C(c(cccc1)c1F)=NC2 Chemical compound Cc1c(Nc(cc2)ccc2C(NCCc2ccncc2)=O)ncc2c1-c(ccc(Cl)c1)c1C(c(cccc1)c1F)=NC2 ARRVXNUBNFJVGT-UHFFFAOYSA-N 0.000 description 1
- ISMMDEVCMHTOBG-UHFFFAOYSA-N Cc1cc(Nc2nc(-c(ccc(Cl)c3)c3C(c3ccccc3F)=NC3)c3cn2)ccc1C(O)=O Chemical compound Cc1cc(Nc2nc(-c(ccc(Cl)c3)c3C(c3ccccc3F)=NC3)c3cn2)ccc1C(O)=O ISMMDEVCMHTOBG-UHFFFAOYSA-N 0.000 description 1
- DQNYWRYOKXUOAO-UHFFFAOYSA-N Cc1ccccc1C(c1c-2ccc(Cl)c1)=NCc1c-2nc(Nc(cc2)ccc2C(N2CCN(C)CC2)=O)nc1 Chemical compound Cc1ccccc1C(c1c-2ccc(Cl)c1)=NCc1c-2nc(Nc(cc2)ccc2C(N2CCN(C)CC2)=O)nc1 DQNYWRYOKXUOAO-UHFFFAOYSA-N 0.000 description 1
- DLKAWFWEKFAATR-UHFFFAOYSA-N NC(C(C1)NCCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O)=O Chemical compound NC(C(C1)NCCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O)=O DLKAWFWEKFAATR-UHFFFAOYSA-N 0.000 description 1
- WDPNHDXDQKINDC-UHFFFAOYSA-N NC(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c2ccccn2)=NC2)c2cn1)=O Chemical compound NC(CC1)CCN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c2ccccn2)=NC2)c2cn1)=O WDPNHDXDQKINDC-UHFFFAOYSA-N 0.000 description 1
- DEARBBFOQKBFIU-UHFFFAOYSA-N NC(CC1)CN1C(c(c(Cl)c1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O Chemical compound NC(CC1)CN1C(c(c(Cl)c1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O DEARBBFOQKBFIU-UHFFFAOYSA-N 0.000 description 1
- QSSNZICYKMCABB-UHFFFAOYSA-N NC(CCC1)CN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O Chemical compound NC(CCC1)CN1C(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1)=O QSSNZICYKMCABB-UHFFFAOYSA-N 0.000 description 1
- XMPDNRKDICEXIA-UHFFFAOYSA-N NC1CC(CC(c(cc2)ccc2Nc2cc(-c(ccc(Cl)c3)c3C(c(cccc3)c3F)=NC3)c3cn2)=O)CC1 Chemical compound NC1CC(CC(c(cc2)ccc2Nc2cc(-c(ccc(Cl)c3)c3C(c(cccc3)c3F)=NC3)c3cn2)=O)CC1 XMPDNRKDICEXIA-UHFFFAOYSA-N 0.000 description 1
- DNYSGUARLAYSPH-UHFFFAOYSA-N O=C(C1CCNCC1)Nc(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1 Chemical compound O=C(C1CCNCC1)Nc(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(c(F)ccc2)c2F)=NC2)c2cn1 DNYSGUARLAYSPH-UHFFFAOYSA-N 0.000 description 1
- VISWMAKUZGDUBM-UHFFFAOYSA-N O=C(CC1CCNCC1)c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c2ccccc2F)=NC2)c2cn1 Chemical compound O=C(CC1CCNCC1)c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c2ccccc2F)=NC2)c2cn1 VISWMAKUZGDUBM-UHFFFAOYSA-N 0.000 description 1
- RHHGRLUONLSEPM-UHFFFAOYSA-N O=C(Cc(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2F)=NC2)c2cn1)NCCN1CCOCC1 Chemical compound O=C(Cc(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2F)=NC2)c2cn1)NCCN1CCOCC1 RHHGRLUONLSEPM-UHFFFAOYSA-N 0.000 description 1
- OPGKIKBZSPBGEO-UHFFFAOYSA-N O=C(c(cc1)ccc1NC[n+]1cc(CN=C(c(cccc2)c2F)c2cc(Cl)ccc2-2)c-2[n-]1)NCCc1c[nH]cn1 Chemical compound O=C(c(cc1)ccc1NC[n+]1cc(CN=C(c(cccc2)c2F)c2cc(Cl)ccc2-2)c-2[n-]1)NCCc1c[nH]cn1 OPGKIKBZSPBGEO-UHFFFAOYSA-N 0.000 description 1
- JTAXVNQSWTUGCT-UHFFFAOYSA-N OC(Cc1cccc(Nc2nc(-c(ccc(Cl)c3)c3C(c(cccc3)c3F)=NC3)c3cn2)c1)=O Chemical compound OC(Cc1cccc(Nc2nc(-c(ccc(Cl)c3)c3C(c(cccc3)c3F)=NC3)c3cn2)c1)=O JTAXVNQSWTUGCT-UHFFFAOYSA-N 0.000 description 1
- VPYXEEVPFJNYOD-UHFFFAOYSA-N OC(c(c(Cl)c1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2F)=NC2)c2cn1)=O Chemical compound OC(c(c(Cl)c1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c(cccc2)c2F)=NC2)c2cn1)=O VPYXEEVPFJNYOD-UHFFFAOYSA-N 0.000 description 1
- RQGDZCBUSDNJIX-UHFFFAOYSA-N OC(c(c(F)c1)ccc1Nc1nc(-c(c(C(c(cccc2)c2F)=NC2)c3)ccc3Cl)c2cn1)=O Chemical compound OC(c(c(F)c1)ccc1Nc1nc(-c(c(C(c(cccc2)c2F)=NC2)c3)ccc3Cl)c2cn1)=O RQGDZCBUSDNJIX-UHFFFAOYSA-N 0.000 description 1
- AWOMDXQZGZBQSH-UHFFFAOYSA-N OC(c(cc1)ccc1Nc(nc1c(c2c3)ccc3Cl)ncc1nc2-c(c(F)ccc1)c1F)=O Chemical compound OC(c(cc1)ccc1Nc(nc1c(c2c3)ccc3Cl)ncc1nc2-c(c(F)ccc1)c1F)=O AWOMDXQZGZBQSH-UHFFFAOYSA-N 0.000 description 1
- ATSOFYUMBYNLAW-UHFFFAOYSA-N OC(c(cc1)ccc1Nc1nc(-c(c(C(c(cccc2)c2F)=NC2)c3)cc(Cl)c3Cl)c2cn1)=O Chemical compound OC(c(cc1)ccc1Nc1nc(-c(c(C(c(cccc2)c2F)=NC2)c3)cc(Cl)c3Cl)c2cn1)=O ATSOFYUMBYNLAW-UHFFFAOYSA-N 0.000 description 1
- BZVMGBNSNLBDNB-UHFFFAOYSA-N OC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c2cc(F)ccc2F)=NC2)c2cn1)=O Chemical compound OC(c(cc1)ccc1Nc1nc(-c(ccc(Cl)c2)c2C(c2cc(F)ccc2F)=NC2)c2cn1)=O BZVMGBNSNLBDNB-UHFFFAOYSA-N 0.000 description 1
- GKCWESFHJXQXBK-UHFFFAOYSA-N OC(c(cc1)ccc1Nc1ncc(C=NC(c(c(F)c2)ccc2F)c2cc(Cl)ccc2-2)c-2n1)=O Chemical compound OC(c(cc1)ccc1Nc1ncc(C=NC(c(c(F)c2)ccc2F)c2cc(Cl)ccc2-2)c-2n1)=O GKCWESFHJXQXBK-UHFFFAOYSA-N 0.000 description 1
- KJNRAVVRLVUXLP-UHFFFAOYSA-N OC(c1c(C=[IH])ccc(Nc2nc(-c(ccc(Cl)c3)c3C(c3ccccc3F)=NC3)c3cn2)c1)=O Chemical compound OC(c1c(C=[IH])ccc(Nc2nc(-c(ccc(Cl)c3)c3C(c3ccccc3F)=NC3)c3cn2)c1)=O KJNRAVVRLVUXLP-UHFFFAOYSA-N 0.000 description 1
- OZQDKFYZDFVAEV-UHFFFAOYSA-N OC(c1cc(Nc2cc(-c(ccc(Cl)c3)c3C(c(cccc3)c3F)=NC3)c3cn2)ccc1F)=O Chemical compound OC(c1cc(Nc2cc(-c(ccc(Cl)c3)c3C(c(cccc3)c3F)=NC3)c3cn2)ccc1F)=O OZQDKFYZDFVAEV-UHFFFAOYSA-N 0.000 description 1
- PQXJMERAOLLBRU-UHFFFAOYSA-N OC(c1cc(Nc2nc(-c(ccc(Cl)c3)c3C(c(cccc3)c3F)=NC3)c3cn2)ccc1)=O Chemical compound OC(c1cc(Nc2nc(-c(ccc(Cl)c3)c3C(c(cccc3)c3F)=NC3)c3cn2)ccc1)=O PQXJMERAOLLBRU-UHFFFAOYSA-N 0.000 description 1
- JGBLDVPNMPXIDS-UHFFFAOYSA-N [Re]c1nc(NC2CCCCC2)nc-2c1CN=C(C1=CCC=C1)c1ccccc-21 Chemical compound [Re]c1nc(NC2CCCCC2)nc-2c1CN=C(C1=CCC=C1)c1ccccc-21 JGBLDVPNMPXIDS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57165304P | 2004-05-14 | 2004-05-14 | |
| US61722104P | 2004-10-08 | 2004-10-08 | |
| PCT/US2005/016445 WO2005111039A2 (en) | 2004-05-14 | 2005-05-12 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008122788A Division JP5148358B2 (ja) | 2004-05-14 | 2008-05-08 | Ａｕｒｏｒａキナーゼの阻害により有糸分裂の進行を阻止するための化合物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007537268A JP2007537268A (ja) | 2007-12-20 |
| JP2007537268A5 true JP2007537268A5 (https=) | 2008-06-26 |
| JP4467616B2 JP4467616B2 (ja) | 2010-05-26 |
Family
ID=35262144
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513304A Expired - Lifetime JP4467616B2 (ja) | 2004-05-14 | 2005-05-12 | Ａｕｒｏｒａキナーゼの阻害により有糸分裂の進行を阻止するための化合物および方法 |
| JP2008122788A Expired - Lifetime JP5148358B2 (ja) | 2004-05-14 | 2008-05-08 | Ａｕｒｏｒａキナーゼの阻害により有糸分裂の進行を阻止するための化合物および方法 |
| JP2011203714A Withdrawn JP2012006972A (ja) | 2004-05-14 | 2011-09-16 | Ａｕｒｏｒａキナーゼの阻害により有糸分裂の進行を阻止するための化合物および方法 |
| JP2014026015A Expired - Lifetime JP5827708B2 (ja) | 2004-05-14 | 2014-02-14 | Ａｕｒｏｒａキナーゼの阻害により有糸分裂の進行を阻止するための化合物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008122788A Expired - Lifetime JP5148358B2 (ja) | 2004-05-14 | 2008-05-08 | Ａｕｒｏｒａキナーゼの阻害により有糸分裂の進行を阻止するための化合物および方法 |
| JP2011203714A Withdrawn JP2012006972A (ja) | 2004-05-14 | 2011-09-16 | Ａｕｒｏｒａキナーゼの阻害により有糸分裂の進行を阻止するための化合物および方法 |
| JP2014026015A Expired - Lifetime JP5827708B2 (ja) | 2004-05-14 | 2014-02-14 | Ａｕｒｏｒａキナーゼの阻害により有糸分裂の進行を阻止するための化合物および方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (9) | US7572784B2 (https=) |
| EP (4) | EP2261226B1 (https=) |
| JP (4) | JP4467616B2 (https=) |
| KR (3) | KR20120091275A (https=) |
| CN (1) | CN104193750B (https=) |
| AR (1) | AR049277A1 (https=) |
| AT (1) | ATE381566T1 (https=) |
| AU (1) | AU2005243175B2 (https=) |
| BR (1) | BRPI0511139B8 (https=) |
| CA (1) | CA2565411C (https=) |
| CY (2) | CY1108092T1 (https=) |
| DE (1) | DE602005003951T4 (https=) |
| DK (1) | DK1771450T5 (https=) |
| EA (1) | EA012112B1 (https=) |
| ES (3) | ES2540987T3 (https=) |
| HR (2) | HRP20080120T5 (https=) |
| IL (1) | IL179063A (https=) |
| MX (1) | MXPA06013042A (https=) |
| MY (1) | MY139355A (https=) |
| NZ (1) | NZ551370A (https=) |
| PL (1) | PL1771450T3 (https=) |
| PT (2) | PT1771450E (https=) |
| RS (2) | RS52436B (https=) |
| TW (1) | TWI338688B (https=) |
| WO (1) | WO2005111039A2 (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2540987T3 (es) * | 2004-05-14 | 2015-07-15 | Millennium Pharmaceuticals, Inc. | Métodos para preparar inhibidores de la aurora cinasa |
| AU2005294575B2 (en) | 2004-10-04 | 2011-11-24 | Millennium Pharmaceuticals, Inc. | Lactam compounds useful as protein kinase inhibitors |
| EP1813609B1 (en) * | 2004-10-29 | 2013-06-19 | Msd K.K. | Novel aminopyridine derivatives having selective aurora-a inhibitory effect |
| AU2006241825A1 (en) | 2005-04-28 | 2006-11-09 | Mitsubishi Tanabe Pharma Corporation | Cyanopyridine derivative and use thereof as medicine |
| BRPI0610368A8 (pt) * | 2005-05-05 | 2015-09-08 | Glaxosmithkline Ip Dev Ltd | Modulação de enzima e de receptor |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| WO2007087246A2 (en) * | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Jak2 tyrosine kinase inhibition |
| BRPI0709612A2 (pt) * | 2006-03-15 | 2011-07-19 | Wyeth Corp | composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i |
| JP2009530342A (ja) * | 2006-03-20 | 2009-08-27 | エフ．ホフマン−ラ ロシュ アーゲー | Ｂｔｋおよびｓｙｋ蛋白キナーゼを阻害する方法 |
| EP2027086B1 (en) * | 2006-05-19 | 2011-11-16 | Wyeth LLC | N-benzoyl-pyrrolidin-3-ylamines as histamine-3 antagonists |
| US7718648B2 (en) | 2006-08-09 | 2010-05-18 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| PE20081152A1 (es) * | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| AU2012203952B2 (en) * | 2006-11-16 | 2014-12-11 | Millennium Pharmaceuticals, Inc. | Compounds for inhibiting mitotic progression |
| AU2014280932B2 (en) * | 2006-11-16 | 2016-10-06 | Millennium Pharmaceuticals, Inc. | Compounds for inhibiting mitotic progression |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| TW200901983A (en) * | 2007-05-24 | 2009-01-16 | Wyeth Corp | Azacyclylbenzamide derivatives as histamine-3 antagonists |
| TW200914457A (en) | 2007-05-31 | 2009-04-01 | Kyowa Hakko Kogyo Kk | Pyrimidodiazepinone derivative |
| CA2693138A1 (en) * | 2007-07-16 | 2009-01-22 | Wyeth Llc | Aminoalkylazole derivatives as histamine-3 antagonists |
| CA2698847A1 (en) * | 2007-09-04 | 2009-03-12 | Biolipox Ab | Bis-aromatic compounds useful in the treatment of inflammation |
| TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
| EA201000316A1 (ru) * | 2007-09-12 | 2010-10-29 | ВАЙЕТ ЭлЭлСи | Производные изохинолинила и изоиндолинила в качестве антагонистов гистаминовых рецепторов 3 подтипа |
| JP2009108036A (ja) * | 2007-09-28 | 2009-05-21 | Fujifilm Corp | 新規アセチレン化合物、その製造方法、それを構成単位として含むポリマー、該化合物及び／又は該ポリマーを含む組成物、該組成物を硬化させてなる硬化物 |
| GB0803747D0 (en) * | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
| US8778953B2 (en) * | 2008-02-29 | 2014-07-15 | Chroma Therapeutics Ltd. | Inhibitors of P38 map kinase |
| KR101667822B1 (ko) | 2008-04-30 | 2016-10-19 | 내셔날 헬스 리서치 인스티튜트 | 오로라 키나아제 저해제용 접합 2고리 피리미딘 화합물 |
| US20110112193A1 (en) * | 2008-05-14 | 2011-05-12 | Peter Nilsson | Bis-aryl compounds for use as medicaments |
| US7998952B2 (en) * | 2008-12-05 | 2011-08-16 | Millennium Pharmaceuticals, Inc. | Thiolactams and uses thereof |
| RU2535032C2 (ru) * | 2008-12-22 | 2014-12-10 | Милленниум Фармасьютикалз, Инк. | Сочетание ингибиторов аврора киназы и анти-cd 20 антител |
| JP2012520275A (ja) | 2009-03-12 | 2012-09-06 | バイオリポックス エービー | Ｌｔｃ４シンターゼ阻害剤としての使用のためのビス芳香族化合物 |
| CA2754946A1 (en) | 2009-03-12 | 2010-09-16 | Biolipox Ab | Bis aromatic compounds for use as ltc4 synthase inhibitors |
| WO2011110824A1 (en) | 2010-03-12 | 2011-09-15 | Biolipox Ab | Bis aromatic compounds for use as ltc4 synthase inhibitors |
| JP2012520276A (ja) | 2009-03-12 | 2012-09-06 | バイオリポックス エービー | Ｌｔｃ４シンターゼ阻害剤としての使用のためのビス芳香族化合物 |
| CA2754941A1 (en) | 2009-03-12 | 2010-09-16 | Biolipox Ab | Bis aromatic compounds for use as ltc4 synthase inhibitors |
| US8546377B2 (en) * | 2009-04-23 | 2013-10-01 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
| US8518933B2 (en) * | 2009-04-23 | 2013-08-27 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
| JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| CA2788774A1 (en) | 2010-02-19 | 2011-08-25 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate |
| AR086656A1 (es) | 2011-06-03 | 2014-01-15 | Millennium Pharm Inc | Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a |
| GB201202027D0 (en) * | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| US20150087687A1 (en) | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| CN103804391A (zh) * | 2012-11-01 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| CN103408552B (zh) * | 2013-07-25 | 2015-07-01 | 苏州明锐医药科技有限公司 | 阿立塞替的制备方法 |
| EP3076963A4 (en) | 2013-12-06 | 2017-09-13 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd30 antibodies |
| JP2018524292A (ja) | 2015-07-21 | 2018-08-30 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | オーロラキナーゼインヒビターと化学療法剤の投与 |
| US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
| JPWO2020130125A1 (ja) | 2018-12-21 | 2021-11-04 | 第一三共株式会社 | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
| US20220305048A1 (en) | 2019-08-26 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
| CN112062768B (zh) * | 2020-07-20 | 2021-08-31 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 具有Aurora激酶降解活性的小分子及其制备方法和应用 |
| KR20230091052A (ko) * | 2021-12-14 | 2023-06-22 | (주)프레이저테라퓨틱스 | 폴리유비퀴틴화에 의한 표적 단백질 또는 폴리펩티드의 분해용 신규 화합물 |
| WO2025087695A1 (en) | 2023-10-23 | 2025-05-01 | Ascend Advanced Therapies Ltd | Method for producing recombinant adeno-associated virus particles |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022801A (en) | 1974-06-03 | 1977-05-10 | Ciba-Geigy Corporation | Pyrazolobenzazepines |
| US3947585A (en) * | 1974-06-03 | 1976-03-30 | Ciba-Geigy Corporation | Pyrazolobenzazepines |
| US4028381A (en) | 1975-05-05 | 1977-06-07 | Ciba-Geigy Corporation | Pyrazolobenzazepines |
| US4099012A (en) * | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| ZA80492B (en) * | 1979-02-07 | 1981-01-28 | Hoffmann La Roche | Benzazepine derivatives |
| KR840000061B1 (ko) | 1979-02-07 | 1984-01-31 | 에프. 호프만-라 롯슈 앤드 캄파니 아크티엔 게젤샤프트 | 벤즈아제핀 유도체의 제조방법 |
| US4481142A (en) * | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
| US4547581A (en) | 1979-02-07 | 1985-10-15 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines and intermediates in their preparation |
| US4318854A (en) | 1979-02-07 | 1982-03-09 | Hoffmann-La Roche Inc. | Intermediates in the production of 2-benzazepines |
| CA1138863A (en) | 1979-02-07 | 1983-01-04 | Norman W. Gilman | Benzazepine-derivatives |
| US4469633A (en) * | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
| NL8102182A (nl) | 1981-05-04 | 1982-12-01 | Philips Nv | Kleurenbeeldbuis. |
| EP0273697A3 (en) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-benzazepines with 5- and 6- membered heterocyclic rings |
| US5166151A (en) * | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5210082A (en) * | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
| US5747487A (en) | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| KR19990087585A (ko) | 1996-03-08 | 1999-12-27 | 돈 리사 로얄 | 신경학적 활성제로서의 아졸로벤즈아제핀 유도체 |
| US6057329A (en) * | 1996-12-23 | 2000-05-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives |
| DK1026167T3 (da) | 1997-09-29 | 2003-05-26 | Meiji Seika Kaisha | Tricykliske triazolobenzazepinderivater, fremgangsmåde til fremstilling af disse samt antiallergiske midler |
| US6277844B1 (en) * | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| US6417207B1 (en) | 1999-05-12 | 2002-07-09 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1317450B1 (en) * | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| NZ526472A (en) * | 2000-12-21 | 2004-04-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| JP4364637B2 (ja) | 2001-08-09 | 2009-11-18 | アクテリオン ファーマシューティカルズ リミテッド | 新規なベンゾ縮合へテロ環化合物 |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| ES2540987T3 (es) * | 2004-05-14 | 2015-07-15 | Millennium Pharmaceuticals, Inc. | Métodos para preparar inhibidores de la aurora cinasa |
| JP2008520713A (ja) | 2004-11-17 | 2008-06-19 | ミイカナ セラピューティクス インコーポレイテッド | キナーゼ阻害剤 |
| US20100160324A1 (en) | 2004-12-30 | 2010-06-24 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
-
2005
- 2005-05-12 ES ES10178391.8T patent/ES2540987T3/es not_active Expired - Lifetime
- 2005-05-12 MX MXPA06013042A patent/MXPA06013042A/es active IP Right Grant
- 2005-05-12 RS RS20120416A patent/RS52436B/sr unknown
- 2005-05-12 DE DE602005003951T patent/DE602005003951T4/de not_active Expired - Lifetime
- 2005-05-12 KR KR1020127014200A patent/KR20120091275A/ko not_active Ceased
- 2005-05-12 RS RS20080109A patent/RS50568B8/sr unknown
- 2005-05-12 KR KR1020067026332A patent/KR101792651B1/ko not_active Expired - Lifetime
- 2005-05-12 AT AT05779921T patent/ATE381566T1/de active
- 2005-05-12 PT PT05779921T patent/PT1771450E/pt unknown
- 2005-05-12 JP JP2007513304A patent/JP4467616B2/ja not_active Expired - Lifetime
- 2005-05-12 US US11/127,855 patent/US7572784B2/en active Active
- 2005-05-12 BR BRPI0511139A patent/BRPI0511139B8/pt not_active IP Right Cessation
- 2005-05-12 ES ES05779921T patent/ES2299080T3/es not_active Expired - Lifetime
- 2005-05-12 CN CN201410345955.0A patent/CN104193750B/zh not_active Expired - Lifetime
- 2005-05-12 PL PL05779921T patent/PL1771450T3/pl unknown
- 2005-05-12 CA CA2565411A patent/CA2565411C/en not_active Expired - Lifetime
- 2005-05-12 EP EP10178391.8A patent/EP2261226B1/en not_active Expired - Lifetime
- 2005-05-12 KR KR1020137013571A patent/KR101748290B1/ko not_active Expired - Lifetime
- 2005-05-12 DK DK05779921.5T patent/DK1771450T5/da active
- 2005-05-12 WO PCT/US2005/016445 patent/WO2005111039A2/en not_active Ceased
- 2005-05-12 EP EP05779921A patent/EP1771450B9/en not_active Expired - Lifetime
- 2005-05-12 PT PT07024446T patent/PT1905773E/pt unknown
- 2005-05-12 AU AU2005243175A patent/AU2005243175B2/en not_active Expired
- 2005-05-12 EP EP13189940.3A patent/EP2746285B1/en not_active Expired - Lifetime
- 2005-05-12 MY MYPI20052151A patent/MY139355A/en unknown
- 2005-05-12 EP EP13189935.3A patent/EP2719698B1/en not_active Expired - Lifetime
- 2005-05-12 NZ NZ551370A patent/NZ551370A/en not_active IP Right Cessation
- 2005-05-12 ES ES07024446T patent/ES2391577T3/es not_active Expired - Lifetime
- 2005-05-12 HR HRP20080120TT patent/HRP20080120T5/hr unknown
- 2005-05-12 EA EA200602100A patent/EA012112B1/ru not_active IP Right Cessation
- 2005-05-13 TW TW094115612A patent/TWI338688B/zh not_active IP Right Cessation
- 2005-05-16 AR ARP050102001A patent/AR049277A1/es unknown
-
2006
- 2006-11-06 IL IL179063A patent/IL179063A/en active IP Right Grant
- 2006-12-21 US US11/643,600 patent/US20070185087A1/en not_active Abandoned
-
2008
- 2008-03-17 CY CY20081100297T patent/CY1108092T1/el unknown
- 2008-05-08 JP JP2008122788A patent/JP5148358B2/ja not_active Expired - Lifetime
-
2009
- 2009-05-27 US US12/472,583 patent/US8399659B2/en active Active
-
2011
- 2011-09-16 JP JP2011203714A patent/JP2012006972A/ja not_active Withdrawn
-
2012
- 2012-10-02 HR HRP20120785TT patent/HRP20120785T1/hr unknown
- 2012-10-03 US US13/644,216 patent/US9102678B2/en not_active Expired - Lifetime
- 2012-10-16 CY CY20121100962T patent/CY1113192T1/el unknown
-
2014
- 2014-02-14 JP JP2014026015A patent/JP5827708B2/ja not_active Expired - Lifetime
-
2015
- 2015-07-27 US US14/810,225 patent/US9765078B2/en not_active Expired - Lifetime
-
2017
- 2017-09-18 US US15/707,484 patent/US10414770B2/en not_active Expired - Lifetime
-
2019
- 2019-09-13 US US16/569,809 patent/US11014928B2/en not_active Expired - Lifetime
-
2021
- 2021-05-24 US US17/328,618 patent/US20220041605A1/en not_active Abandoned
-
2023
- 2023-10-19 US US18/490,596 patent/US20240083906A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11014928B2 (en) | Compounds and methods for inhibiting mitotic progression | |
| JP2007537268A5 (https=) | ||
| EP1905773B1 (en) | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | |
| HK1197592A (en) | Methods for preparing aurora kinase inhibitors | |
| HK1205102B (en) | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | |
| HK1114853B (en) | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | |
| HK1197592B (en) | Methods for preparing aurora kinase inhibitors | |
| HK1102500B (en) | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | |
| HK1102500C (en) | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |